(Q53938618)

22 May 2018

title

Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. (English)

1 reference

22 May 2018

author name string

Pearson PA

1

1 reference

22 May 2018

Piracha AR

2

1 reference

22 May 2018

Sen HA

3

1 reference

22 May 2018

Jaffe GJ

4

1 reference

22 May 2018

publication date

1 January 1999

1 reference

22 May 2018

published in

Ophthalmology

1 reference

22 May 2018

volume

106

1 reference

22 May 2018

issue

1

1 reference

22 May 2018

page(s)

148-153

1 reference

22 May 2018

Variations in Recurrent Active Toxoplasmic Retinochoroiditis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

Therapy for ocular toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

Evaluation of the Effect of Drugs on the Cyst Form of Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

Examination of some factors responsible for a food-induced increase in absorption of atovaquone

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

THERAPY OF TOXOPLASMOSIS UVEITIS

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

Clindamycin in the treatment of toxoplasmic retinochoroiditis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

[Treatment of toxoplasmosis retinochoroiditis with atovaquone in an immunocompetent patient]

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990021-0

7 January 2021

10.1016/S0161-6420(99)90021-0

Identifiers

DOI

1 reference

22 May 2018

PubMed ID

9917796

1 reference

22 May 2018